Gilead Sciences Inc (GILD): ASCO: Outcomes of patients (pts) ≥ 65...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	30
Posts	2777
Boards Moderated	3
Alias Born	10/24/2015

jondoeuk

Re: None

Wednesday, 04/17/2019 3:39:00 PM

Wednesday, April 17, 2019 3:39:00 PM

ASCO: Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B cell lymphoma (LBCL) https://meetinglibrary.asco.org/record/171950/abstract

End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) https://meetinglibrary.asco.org/record/173638/abstract

ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) https://meetinglibrary.asco.org/record/177917/abstract

ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B cell lymphoma (LBCL) https://meetinglibrary.asco.org/record/177950/abstract